Bainbridge Island, Wash.-based Solius Labs announced $23M in Series A funding on Wednesday along with the launch of the Solius Pro: a $2,995 UVB (Ultraviolet B) light therapy device for home and professional use.
The device scans a user’s skin to calculate a personalized dose of UVB light at a targeted 293-nanometer wavelength. Solius Pro delivers light therapy to the user’s back in a single weekly session of less than five minutes, and is controlled via a smartphone app.